CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
RAD001 +1 moredrug
Likely dose
RAD001 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00474929
NCT00474929Phase 2Completed
CompareCT.gov

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma

Mayo Clinic·interventional·Posted May 17, 2007·Updated Aug 20, 2019

In Brief

A Phase 2 clinical trial evaluating RAD001 and Sorafenib for Lymphoma and Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 103 participants across 2 sites.

Detailed Summary

RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib and everolimus and to see how well they work in treating patients with relapsed or refractory non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Multiple Myeloma and Plasma Cell Neoplasm
CountriesUnited States
CollaboratorsUniversity of Iowa

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartAug 29, 2007
Primary CompletionNov 5, 2011
Study CompletionAug 8, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 19.1 years ago

Interventions

RAD001drug

Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;

Sorafenibdrug

Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;